Positive prostate biopsy laterality and implications for staging

Mark K. Buyyounouski, Eric M. Horwitz, Alexandra L. Hanlon, Robert G. Uzzo, Gerald E. Hanks, Alan Pollack

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives. To examine the effect of including positive prostate biopsy information in palpation staging (2002 system) and the influence of this information on freedom from biochemical failure (bNED). Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used. Methods. From April 1, 1989 to September 30, 1999, 1038 patients with palpable T1-T3Nx-0M0 prostate cancer were treated with three-dimensional conformal radiotherapy alone. Kaplan-Meier bNED curves were compared using the log-rank test. The Cox proportional hazards regression model of bNED was used for multivariate analysis. Results. The median follow-up was 46 months. The proportion of patients with bilateral positive biopsies by palpation category T1c was 24%, by T2a was 17%, by T2b was 26%, by T2c was 65%, and by T3 was 53%. No statistically significant difference was noted in bNED on the basis of biopsy laterality status for the palpation T stages T1c, T2a, T2b, or T3. A statistically significant difference in the 5-year bNED in the T2c stage was found; those with unilateral positive biopsies fared worse (46% versus 74%, respectively, P = 0.04). Conclusions. Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used.

Original languageEnglish
Pages (from-to)298-303
Number of pages6
JournalUrology
Volume62
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Prostate
Biopsy
Palpation
Conformal Radiotherapy
Proportional Hazards Models
Information Systems
Prostatic Neoplasms
Multivariate Analysis
Joints
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., Hanks, G. E., & Pollack, A. (2003). Positive prostate biopsy laterality and implications for staging. Urology, 62(2), 298-303. https://doi.org/10.1016/S0090-4295(03)00334-0

Positive prostate biopsy laterality and implications for staging. / Buyyounouski, Mark K.; Horwitz, Eric M.; Hanlon, Alexandra L.; Uzzo, Robert G.; Hanks, Gerald E.; Pollack, Alan.

In: Urology, Vol. 62, No. 2, 01.08.2003, p. 298-303.

Research output: Contribution to journalArticle

Buyyounouski, MK, Horwitz, EM, Hanlon, AL, Uzzo, RG, Hanks, GE & Pollack, A 2003, 'Positive prostate biopsy laterality and implications for staging', Urology, vol. 62, no. 2, pp. 298-303. https://doi.org/10.1016/S0090-4295(03)00334-0
Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, Pollack A. Positive prostate biopsy laterality and implications for staging. Urology. 2003 Aug 1;62(2):298-303. https://doi.org/10.1016/S0090-4295(03)00334-0
Buyyounouski, Mark K. ; Horwitz, Eric M. ; Hanlon, Alexandra L. ; Uzzo, Robert G. ; Hanks, Gerald E. ; Pollack, Alan. / Positive prostate biopsy laterality and implications for staging. In: Urology. 2003 ; Vol. 62, No. 2. pp. 298-303.
@article{8a688381ab6444158935d01a7555523b,
title = "Positive prostate biopsy laterality and implications for staging",
abstract = "Objectives. To examine the effect of including positive prostate biopsy information in palpation staging (2002 system) and the influence of this information on freedom from biochemical failure (bNED). Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used. Methods. From April 1, 1989 to September 30, 1999, 1038 patients with palpable T1-T3Nx-0M0 prostate cancer were treated with three-dimensional conformal radiotherapy alone. Kaplan-Meier bNED curves were compared using the log-rank test. The Cox proportional hazards regression model of bNED was used for multivariate analysis. Results. The median follow-up was 46 months. The proportion of patients with bilateral positive biopsies by palpation category T1c was 24{\%}, by T2a was 17{\%}, by T2b was 26{\%}, by T2c was 65{\%}, and by T3 was 53{\%}. No statistically significant difference was noted in bNED on the basis of biopsy laterality status for the palpation T stages T1c, T2a, T2b, or T3. A statistically significant difference in the 5-year bNED in the T2c stage was found; those with unilateral positive biopsies fared worse (46{\%} versus 74{\%}, respectively, P = 0.04). Conclusions. Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used.",
author = "Buyyounouski, {Mark K.} and Horwitz, {Eric M.} and Hanlon, {Alexandra L.} and Uzzo, {Robert G.} and Hanks, {Gerald E.} and Alan Pollack",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0090-4295(03)00334-0",
language = "English",
volume = "62",
pages = "298--303",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Positive prostate biopsy laterality and implications for staging

AU - Buyyounouski, Mark K.

AU - Horwitz, Eric M.

AU - Hanlon, Alexandra L.

AU - Uzzo, Robert G.

AU - Hanks, Gerald E.

AU - Pollack, Alan

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Objectives. To examine the effect of including positive prostate biopsy information in palpation staging (2002 system) and the influence of this information on freedom from biochemical failure (bNED). Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used. Methods. From April 1, 1989 to September 30, 1999, 1038 patients with palpable T1-T3Nx-0M0 prostate cancer were treated with three-dimensional conformal radiotherapy alone. Kaplan-Meier bNED curves were compared using the log-rank test. The Cox proportional hazards regression model of bNED was used for multivariate analysis. Results. The median follow-up was 46 months. The proportion of patients with bilateral positive biopsies by palpation category T1c was 24%, by T2a was 17%, by T2b was 26%, by T2c was 65%, and by T3 was 53%. No statistically significant difference was noted in bNED on the basis of biopsy laterality status for the palpation T stages T1c, T2a, T2b, or T3. A statistically significant difference in the 5-year bNED in the T2c stage was found; those with unilateral positive biopsies fared worse (46% versus 74%, respectively, P = 0.04). Conclusions. Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used.

AB - Objectives. To examine the effect of including positive prostate biopsy information in palpation staging (2002 system) and the influence of this information on freedom from biochemical failure (bNED). Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used. Methods. From April 1, 1989 to September 30, 1999, 1038 patients with palpable T1-T3Nx-0M0 prostate cancer were treated with three-dimensional conformal radiotherapy alone. Kaplan-Meier bNED curves were compared using the log-rank test. The Cox proportional hazards regression model of bNED was used for multivariate analysis. Results. The median follow-up was 46 months. The proportion of patients with bilateral positive biopsies by palpation category T1c was 24%, by T2a was 17%, by T2b was 26%, by T2c was 65%, and by T3 was 53%. No statistically significant difference was noted in bNED on the basis of biopsy laterality status for the palpation T stages T1c, T2a, T2b, or T3. A statistically significant difference in the 5-year bNED in the T2c stage was found; those with unilateral positive biopsies fared worse (46% versus 74%, respectively, P = 0.04). Conclusions. Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used.

UR - http://www.scopus.com/inward/record.url?scp=0042624704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042624704&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(03)00334-0

DO - 10.1016/S0090-4295(03)00334-0

M3 - Article

C2 - 12893339

AN - SCOPUS:0042624704

VL - 62

SP - 298

EP - 303

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -